LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

Authors: J-P. Machiels, Yungan Tao, Barbara Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P. Figueiredo Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, Simon Laban, R. Greil, M. Burian, M. Hetnal, L.F. Licitra, R. Swaby, Y. Zhang, B. Gumuscu, B. Bidadi, L.L. Siu - Annals of Oncology 2022 cited by 91